Summary
This piece cuts through hype to tally quantum chemistry’s real prospects. It finds credible, defensible advantage for a narrow class of problems with strongly correlated electrons. The resource estimates are specific and align with plausible hardware timelines. The scope is smaller than many pitch decks suggest.
For drug discovery, catalysis, and materials, the near-term value is in focused subproblems where classical methods struggle. Full product pipelines still rely on modeling, data curation, synthesis, and validation that quantum does not accelerate. Expect practical gains from hybrid workflows and careful problem selection, not a universal speedup.
For CISOs and quantum security leaders, the message is calibration and timing. Prepare for secure integration of early quantum services into HPC stacks, but resist hype-driven commitments. Track vendor claims against concrete resource estimates and the availability of error-corrected capacity. This domain will not shift cryptanalytic risk soon, yet it will affect data governance, supply-chain trust, and standards as quantum enters R&D operations.
Read more
See the original article at: https://postquantum.com/quantum-utility-map/quantum-chemistry-drug-discovery-catalysis/